JP2023520969A5 - - Google Patents
Info
- Publication number
- JP2023520969A5 JP2023520969A5 JP2022548950A JP2022548950A JP2023520969A5 JP 2023520969 A5 JP2023520969 A5 JP 2023520969A5 JP 2022548950 A JP2022548950 A JP 2022548950A JP 2022548950 A JP2022548950 A JP 2022548950A JP 2023520969 A5 JP2023520969 A5 JP 2023520969A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- antibody
- seq
- antibody according
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063006695P | 2020-04-07 | 2020-04-07 | |
| US63/006,695 | 2020-04-07 | ||
| US202163158265P | 2021-03-08 | 2021-03-08 | |
| US63/158,265 | 2021-03-08 | ||
| PCT/US2021/025775 WO2021207072A1 (en) | 2020-04-07 | 2021-04-05 | Anti-tmprss6 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023520969A JP2023520969A (ja) | 2023-05-23 |
| JP2023520969A5 true JP2023520969A5 (OSRAM) | 2024-04-26 |
| JP7813234B2 JP7813234B2 (ja) | 2026-02-12 |
Family
ID=75888147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548950A Active JP7813234B2 (ja) | 2020-04-07 | 2021-04-05 | 抗ｔｍｐｒｓｓ６抗体及びその用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US12215170B2 (OSRAM) |
| EP (1) | EP4126220A1 (OSRAM) |
| JP (1) | JP7813234B2 (OSRAM) |
| KR (1) | KR20230007368A (OSRAM) |
| CN (1) | CN115243762A (OSRAM) |
| AU (1) | AU2021251087A1 (OSRAM) |
| CA (1) | CA3174339A1 (OSRAM) |
| TW (1) | TW202204422A (OSRAM) |
| WO (1) | WO2021207072A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230295345A1 (en) * | 2020-04-07 | 2023-09-21 | Mabwell Therapeutics, Inc. | Anti-tmprss6 antibodies and uses thereof |
| AU2021251087A1 (en) | 2020-04-07 | 2022-12-01 | Mabwell Therapeutics Inc. | Anti-TMPRSS6 antibodies and uses thereof |
| AU2022274888A1 (en) * | 2021-05-11 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Anti-tmprss6 antibodies and uses thereof |
| CN120752046A (zh) * | 2022-11-25 | 2025-10-03 | 迈威(美国)生物治疗有限公司 | 抗tmprss6抗体及其用途 |
| EP4688867A2 (en) * | 2023-04-04 | 2026-02-11 | Disc Medicine, Inc. | Anti-tmprss6 antibodies and uses thereof |
| AU2024243972A1 (en) * | 2023-04-06 | 2025-10-23 | Memorial Hospital For Cancer And Allied Diseases | Il-10 receptor antibodies and methods of use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| US20050054027A1 (en) | 2003-09-09 | 2005-03-10 | Irm Llc | Modulators of transmembrane protease serine 6 |
| GB0614201D0 (en) | 2006-07-18 | 2006-08-23 | Univ Cardiff | Matriptase-2 |
| AR065083A1 (es) * | 2007-02-02 | 2009-05-13 | Amgen Inc | Hepcidina, antagonistas de la hepcidina y metodos de uso |
| WO2013070786A1 (en) * | 2011-11-07 | 2013-05-16 | Isis Pharmaceuticals, Inc. | Modulation of tmprss6 expression |
| AR093620A1 (es) | 2012-12-17 | 2015-06-10 | Lilly Co Eli | Anticuerpos bmp-6 |
| DE112014005975T5 (de) | 2013-12-17 | 2016-09-15 | Kymab Limited | Menschliche Ziele |
| WO2016071701A1 (en) * | 2014-11-07 | 2016-05-12 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
| CA3119498A1 (en) * | 2015-07-31 | 2017-02-09 | Medimmune Limited | Methods for treating hepcidin-mediated disorders |
| GB201815629D0 (en) | 2018-09-25 | 2018-11-07 | Kymab Ltd | Antagonists |
| CA3162880A1 (en) | 2019-11-29 | 2021-06-03 | Kymab Limited | Treatment for physiological iron overload |
| AU2021251087A1 (en) | 2020-04-07 | 2022-12-01 | Mabwell Therapeutics Inc. | Anti-TMPRSS6 antibodies and uses thereof |
| BR112023022284A2 (pt) | 2021-04-26 | 2023-12-26 | Alnylam Pharmaceuticals Inc | Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma |
| AU2022265493A1 (en) | 2021-04-27 | 2023-09-21 | Silence Therapeutics Gmbh | Sirna targeting tmprss6 for the treatment of myeloproliferative disorders |
-
2021
- 2021-04-05 AU AU2021251087A patent/AU2021251087A1/en active Pending
- 2021-04-05 CN CN202180007339.2A patent/CN115243762A/zh active Pending
- 2021-04-05 CA CA3174339A patent/CA3174339A1/en active Pending
- 2021-04-05 EP EP21724822.8A patent/EP4126220A1/en active Pending
- 2021-04-05 US US17/916,008 patent/US12215170B2/en active Active
- 2021-04-05 JP JP2022548950A patent/JP7813234B2/ja active Active
- 2021-04-05 KR KR1020227038805A patent/KR20230007368A/ko active Pending
- 2021-04-05 WO PCT/US2021/025775 patent/WO2021207072A1/en not_active Ceased
- 2021-04-06 TW TW110112433A patent/TW202204422A/zh unknown
-
2023
- 2023-06-05 US US18/329,172 patent/US11866513B2/en active Active
-
2025
- 2025-01-31 US US19/042,342 patent/US20250304719A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024038003A5 (OSRAM) | ||
| JP2020508655A5 (OSRAM) | ||
| JP2021530251A5 (OSRAM) | ||
| JP2022512132A5 (OSRAM) | ||
| JP2010502183A5 (OSRAM) | ||
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| JP2018516853A5 (OSRAM) | ||
| JP2021520832A5 (OSRAM) | ||
| JP2012525829A5 (OSRAM) | ||
| HRP20131215T1 (hr) | Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope | |
| JP2020524510A5 (OSRAM) | ||
| JP2023509390A5 (OSRAM) | ||
| JP2015511817A5 (OSRAM) | ||
| JP2009225799A5 (OSRAM) | ||
| JP2018522888A5 (OSRAM) | ||
| JP2021530244A5 (OSRAM) | ||
| JP2011527899A5 (OSRAM) | ||
| JP2025067915A5 (OSRAM) | ||
| JP2023540526A5 (OSRAM) | ||
| JP2009509538A5 (OSRAM) | ||
| JP2019505477A5 (OSRAM) | ||
| JP2020515277A5 (OSRAM) | ||
| JP2024512135A5 (OSRAM) | ||
| JP2015508056A5 (OSRAM) | ||
| JP2024516098A5 (OSRAM) |